First Long Island Investors LLC Has $22.32 Million Stake in Eli Lilly and Company $LLY

Key Points

• First Long Island Investors LLC increased its stake in Eli Lilly to $22.32 million, raising its holdings by 14.1% in the first quarter, now making up approximately 1.8% of the firm's portfolio.
• Institutional ownership of Eli Lilly stock stands at 82.53%, with various hedge funds adjusting their stakes, including significant increases by WestEnd Advisors and Citizens National Bank.
• Eli Lilly reported a 37.6% increase in revenue year-over-year for the latest quarter, achieving earnings per share of $6.31, surpassing analysts' expectations.

First Long Island Investors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 14.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,020 shares of the company's stock after purchasing an additional 3,336 shares during the period. Eli Lilly and Company comprises about 1.8% of First Long Island Investors LLC's portfolio, making the stock its 22nd largest holding. First Long Island Investors LLC's holdings in Eli Lilly and Company were worth $22,316,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the first quarter valued at $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company in the first quarter valued at $40,000. Finally, TD Capital Management LLC grew its position in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger bought 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $755.85 on Friday. The company has a market capitalization of $715.38 billion, a price-to-earnings ratio of 49.40, a PEG ratio of 1.05 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a 50-day simple moving average of $741.52 and a 200 day simple moving average of $778.38. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Guggenheim decreased their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Finally, Leerink Partners reissued a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.